Physician profile
Michael Kim
NPI 1821229972
$3,985.01
in general payments reported to CMS, 2019-2025
25 companies · $598 in 2025
The $598 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $973 · 2020: $192 · 2021: $654 · 2022: $437 · 2023: $705 · 2024: $426 · 2025: $598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,728.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $763.38 | 2019-2024 | Vemlidy |
| Abbvie INC. | $735.70 | 2019-2024 | |
| Conmed Corporation | $351.14 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $343.63 | 2019-2023 | Xifaxan |
| Celgene Corporation | $313.77 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $257.82 | 2025 | Ibsrela |
| Janssen Biotech, INC. | $199.35 | 2024-2025 | Erleada, Akeega, Stelara |
| Boston Scientific Corporation | $143.11 | 2023 | Spaceoar Vue System - 10ml |
| Sun Pharmaceutical Industries INC. | $114.46 | 2025 | |
| Intuitive Surgical, INC. | $98.22 | 2023 | Da Vinci Surgical System |
| Braintree Laboratories, INC. | $79.69 | 2022 | |
| Phathom Pharmaceuticals, INC. | $69.64 | 2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $67.17 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.13 | 2019-2021 | |
| Qol Medical, LLC | $64.44 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $54.66 | 2021-2024 | Linzess |
| Pfizer INC. | $52.25 | 2019-2020 | |
| Redhill Biopharma INC. | $50.18 | 2021 | |
| Nestle Healthcare Nutrition INC. | $39.05 | 2021 | |
| Madrigal Pharmaceuticals | $35.14 | 2025 | Rezdiffra |
| Genentech USA, INC. | $24.59 | 2021 | |
| Exact Sciences Corporation | $19.92 | 2025 | |
| Alfasigma USA, INC. | $19.39 | 2020 | |
| Shionogi INC | $13.93 | 2019 | |
| Endogastric Solutions, INC | $9.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.